Verismo Therapeutics Reveals Groundbreaking Data on SynKIR™-310 CAR T Therapy at ASH 2025 Verismo Therapeutics presented new preclinical findings on SynKIR™-310, showcasing enhanced tumor control and reduced cytokine release compared to traditional CAR-T therapies.

Verismo Therapeutics Reveals Groundbreaking Data on SynKIR™-310 CAR T Therapy at ASH 2025 #USA #Philadelphia #CAR_T_Therapy #Verismo_Therapeutics #SynKIR-310

Verismo Therapeutics Unveils New Preclinical Findings for SynKIR™-110 at SITC 2025 Verismo Therapeutics has shared groundbreaking preclinical data on SynKIR™-110 during SITC 2025, showcasing its superior efficacy and safety in targeting solid tumors.

Verismo Therapeutics Unveils New Preclinical Findings for SynKIR™-110 at SITC 2025 #USA #Philadelphia #CAR_T_Therapy #Verismo_Therapeutics #SynKIR™

Gilead Sciences Initiates Program to Address Regional Disparities in CAR T Cell Therapy Access Gilead Sciences has adopted proposals from three organizations to improve access to CAR T cell therapy, addressing regional healthcare disparities.

Gilead Sciences Initiates Program to Address Regional Disparities in CAR T Cell Therapy Access #Japan #Tokyo #CAR_T_Therapy #Gilead_Sciences #Kite_Pharma

Revolutionary In Vivo CAR T Therapy Shows Promise for Systemic Lupus Erythematosus Patients MagicRNA's innovative in vivo CAR T therapy shows promising results in systemic lupus erythematosus patients, publishing pivotal findings in NEJM.

Revolutionary In Vivo CAR T Therapy Shows Promise for Systemic Lupus Erythematosus Patients #China #Shenzhen #CAR_T_Therapy #SLE #MagicRNA

Gilead and Kite Set to Showcase Groundbreaking Cancer Data at 2025 ASCO and EHA Meetings Gilead and Kite are slated to unveil innovative findings in oncology during the 2025 ASCO and EHA meetings, heralding advancements in cancer treatments.

Gilead and Kite Set to Showcase Groundbreaking Cancer Data at 2025 ASCO and EHA Meetings #United_States #California #CAR_T_Therapy #Gilead #Kite

AffyImmune to Present CAR T Therapy AIC100 Data at AACR 2025 Conference AffyImmune Therapeutics will showcase its CAR T therapy AIC100 during the AACR 2025 conference, detailing clinical data for advanced thyroid cancer treatment.

AffyImmune to Present CAR T Therapy AIC100 Data at AACR 2025 Conference #United_States #Chicago #AffyImmune #CAR_T_Therapy #AIC100

PeproMene Bio Secures $11M for Innovative CAR T Cell Therapy in Cancer Treatment PeproMene Bio, in collaboration with IFLI, secures an $11 million investment to advance a groundbreaking CAR T cell therapy for follicular lymphoma in clinical trials.

PeproMene Bio Secures $11M for Innovative CAR T Cell Therapy in Cancer Treatment #USA #CAR_T_Therapy #Follicular_Lymphoma #Irvine,_California #PeproMene_Bio

PeproMene Bio Secures $11M Investment to Enhance CAR T Cell Therapy for Lymphoma Patients In a significant boost for cancer therapy, PeproMene Bio has gained an $11 million investment to enhance its promising CAR T cell therapy for treating follicular lymphoma.

PeproMene Bio Secures $11M Investment to Enhance CAR T Cell Therapy for Lymphoma Patients #USA #Irvine #CAR_T_Therapy #Follicular_Lymphoma #PeproMene_Bio

AffyImmune Promotes Dr. Deyaa Adib to Chief Medical Officer AffyImmune Therapeutics has appointed Dr. Deyaa Adib as Chief Medical Officer. His extensive oncology experience aims to enhance clinical development strategies for cancer therapies.

AffyImmune Promotes Dr. Deyaa Adib to Chief Medical Officer #USA #AffyImmune #Deyaa_Adib #CAR_T_Therapy #Natick,_Massachusetts